Top Story Today
Lilly Spent $3.8 Billion on Three Vaccine Companies Before Lunch
Eli Lilly, a company without a modern human vaccine portfolio, acquired three vaccine developers in a single day: Curevo (shingles, up to $1.5B), Vaccine Company (Epstein-Barr virus, up to $1.55B), and LimmaTech (drug-resistant bacteria, up to $780M). The thesis is bold: prevent infections now to stop chronic diseases like MS and cancer later. Lilly also recently hired Peter Marks, the former FDA vaccine chief, to lead its infectious disease push. Most of the $3.8 billion is milestone-based, which tells you the company knows it's buying potential, not certainty.
Why it matters: This is one of the largest coordinated vaccine bets by a non-vaccine company in years, signaling that Lilly sees prevention as the next frontier beyond its GLP-1 empire and is willing to spend its obesity profits building entirely new franchises.
Read more →FDA's Tech Overhaul
The FDA Just Started Watching Clinical Trials in Real Time
The FDA successfully received and validated live data from an AstraZeneca cancer trial, proving for the first time that regulators can monitor studies as they happen instead of reviewing million-page submissions months later. The agency says the approach could cut drug development timelines by 20 to 40%, and Amgen is next in line.
Read more →The FDA Wants the Public to Help Design Its AI Clinical Trial Pilot
The FDA published a formal request for information on how to build an AI-enabled pilot for early-phase trial optimization. Comments close May 29; pilot participants get selected in August. The agency wants AI to improve dose-finding, adaptive trial designs, and safety monitoring. Getting into this pilot means helping write rules the rest of the industry will follow.
Read more →An Algorithm Now Decides If Your Factory Gets a One-Day FDA Inspection
The FDA launched an AI-powered pilot compressing traditional week-long facility inspections into a single day. Nearly 2,000 pharma manufacturing sites are overdue for routine visits, and 46 one-day assessments have already been completed. Lower-risk sites get the speed run; higher-risk ones should expect more scrutiny, not less, as freed-up inspectors are redeployed.
Read more →Deals and Strategy
Zepbound Vials at $449/Month: Price Cut or Volume Play?
Lilly is selling Zepbound's four highest doses as single-dose vials at $449 per month through LillyDirect, roughly 60% below pen prices. Wall Street says the move is earnings-neutral because vials capture cash-paying patients who wouldn't buy pens anyway. It also undercuts compounding pharmacies and gives Lilly political cover as Washington scrutinizes obesity drug pricing.
Read more →Astellas Has a $6 Billion Hole to Fill Before 2027
Astellas unveiled a five-year plan centered on aggressive dealmaking as its prostate cancer blockbuster Xtandi (approximately 10-12% of total revenue) loses U.S. patent protection in August 2027. The company is targeting clinical-stage assets in ADCs, protein degraders, and gene therapies while cutting $1.3 billion in costs by 2030. Another motivated buyer in an already crowded M&A market.
Read more →Funding and Supply Chain
CellCentric Raised $220M for a Cancer Drug Nobody Else Can Make
Cambridge-based CellCentric closed Europe's largest private biotech round of 2026, pulling in $220 million from Venrock, Fidelity, RA Capital, and Pfizer for its first-in-class oral cancer drug targeting p300/CBP proteins. The company says it's funded through 2029 with no need to raise again before pivotal data.
Read more →Brain Surgery's Supply Chain Comes Down to a Missing Sponge
The FDA warned that a nationwide shortage of neurosurgical sponges and patties will persist through the end of 2026 after Medline recalled its entire neuro sponge line over endotoxin contamination. Hospitals are rationing supplies for brain surgery, and the shortage highlights a familiar, uncomfortable pattern: critical medical products optimized for cost, not resilience.
Read more →